51 research outputs found
Critical parameters for the partial coalescence of a droplet
The partial coalescence of a droplet onto a planar liquid/liquid interface is
investigated experimentally by tuning the viscosities of both liquids. The
problem mainly depends on four dimensionless parameters: the Bond number
(gravity vs. surface tension), the Ohnesorge numbers (viscosity in both fluids
vs. surface tension), and the density relative difference. The ratio between
the daughter droplet size and the mother droplet size is investigated as a
function of these dimensionless numbers. Global quantities such as the
available surface energy of the droplet has been measured during the
coalescence. The capillary waves propagation and damping are studied in detail.
The relation between these waves and the partial coalescence is discussed.
Additional viscous mechanisms are proposed in order to explain the asymmetric
role played by both viscosities.Comment: 16 pages, 14 figures, submitted to Physical Review
Beta-blocker migraine prophylaxis affects the excitability of the visual cortex as revealed by transcranial magnetic stimulation
The objective of this study is to assess effects of beta-blocker migraine prophylaxis on cortical excitability determined by transcranial magnetic stimulation (TMS). Phosphene and motor thresholds (PT, MT) were investigated in 29 patients with migraine, in 15 of them prior to and following preventive medication with metoprolol and in 14 patients without prophylaxis. Following prophylaxis headache frequency significantly decreased (p = 0.005) and mean PT were significantly increased (51.5 ± 7.5 vs. 63.6 ± 8.4%) compared to patients without preventive treatment (53.7 ± 5.3 vs. 52.3 ± 6.3%; p = 0.040). Mean MT did not significantly differ either between groups or due to treatment. In the group of all patients, a significant inverse correlation between headache frequency and the level of PT was found (R = −0.629; p < 0.01). There was, however, no significant correlation in the subgroups of patients. We conclude that (a) clinical efficacy of beta-blocker treatment in migraine could be (at least partly) linked to its ability to modulate the excitability of the visual cortex and (b) the PT determined by TMS appears suitable to assess the effects of prophylaxis on cortical excitability in the individual patient. This may be useful in clinical trials investigating migraine preventive drugs
Patch: platelet transfusion in cerebral haemorrhage: study protocol for a multicentre, randomised, controlled trial
<p>Abstract</p> <p>Background</p> <p>Patients suffering from intracerebral haemorrhage have a poor prognosis, especially if they are using antiplatelet therapy. Currently, no effective acute treatment option for intracerebral haemorrhage exists. Limiting the early growth of intracerebral haemorrhage volume which continues the first hours after admission seems a promising strategy. Because intracerebral haemorrhage patients who are on antiplatelet therapy have been shown to be particularly at risk of early haematoma growth, platelet transfusion may have a beneficial effect.</p> <p>Methods/Design</p> <p>The primary objective is to investigate whether platelet transfusion improves outcome in intracerebral haemorrhage patients who are on antiplatelet treatment. The PATCH study is a prospective, randomised, multi-centre study with open treatment and blind endpoint evaluation. Patients will be randomised to receive platelet transfusion within six hours or standard care. The primary endpoint is functional health after three months. The main secondary endpoints are safety of platelet transfusion and the occurrence of haematoma growth. To detect an absolute poor outcome reduction of 20%, a total of 190 patients will be included.</p> <p>Discussion</p> <p>To our knowledge this is the first randomised controlled trial of platelet transfusion for an acute haemorrhagic disease.</p> <p>Trial registration</p> <p>The Netherlands National Trial Register (NTR1303)</p
Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial
Background: S44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical excitability in a transcranial magnetic stimulation study in healthy volunteers. The Randomized Efficacy and Safety Trial of Oral GABAA α5 antagonist S44819 after Recent ischemic Event (RESTORE BRAIN) aimed to evaluate the safety and efficacy of S44819 for enhancing clinical recovery of patients with ischaemic stroke. Methods: RESTORE BRAIN was an international, randomised, double-blind, parallel-group, placebo-controlled, multicentre phase 2 trial that evaluated the safety and efficacy of oral S44189 in patients with recent ischaemic stroke. The study was done in specialised stroke units in 92 actively recruiting centres in 14 countries: ten were European countries (Belgium, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, and the UK) and four were non-European countries (Australia, Brazil, Canada, and South Korea). Patients aged 18–85 years with acute ischaemic stroke involving cerebral cortex (National Institute of Health Stroke Scale [NIHSS] score 7–20) without previous disability were eligible for inclusion. Participants were randomly assigned to receive 150 mg S44819 twice a day, 300 mg S44819 twice a day, or placebo twice a day by a balanced, non-adaptive randomisation method with a 1:1:1 ratio. Treatment randomisation and allocation were centralised via the interactive web response system using computer-generated random sequences with a block size of 3. Blinding of treatment was achieved by identical appearance and taste of all sachets. Patients, investigators and individuals involved in the analysis of the trial were masked to group assignment. The primary endpoint was the modified Rankin Scale (mRS) score 90 days from onset of treatment, evaluated by shift analysis (predefined main analysis) or by dichotomised analyses using 0–1 versus 2–6 and 0–2 versus 3–6 cutoffs (predefined secondary analysis). Secondary endpoints were the effects of S44819 on the NIHSS and Montreal Cognitive Assessment (MoCA) scores, time needed to complete parts A and B of the Trail Making Test, and the Barthel index. Efficacy analyses were done on all patients who received at least one dose of treatment and had at least one mRS score taken after day 5 (specifically, on or after day 30). Safety was compared across treatment groups for all patients who received at least one dose of treatment. The study was registered at ClinicalTrials.gov, NCT02877615. Findings: Between Dec 19, 2016, and Nov 16, 2018, 585 patients were enrolled in the study. Of these, 197 (34%) were randomly assigned to receive 150 mg S44819 twice a day, 195 (33%) to receive 300 mg S44819 twice a day, and 193 (33%) to receive placebo twice a day. 189 (96%) of 197 patients in the 150 mg S44819 group, 188 (96%) of 195 patients in the 300 mg S44819 group, and 191 (99%) patients in the placebo group received at least one dose of treatment and had at least one mRS score taken after day 5, and were included in efficacy analyses. 195 (99%) of 197 patients in the 150 mg S44819 group, 194 (99%) of 195 patients in the 300 mg S44819 group, and 193 (100%) patients in the placebo group received at least one dose of treatment, and were included in safety analyses. The primary endpoint of mRS at day 90 did not differ between each of the two S44819 groups and the placebo group (OR 0·91 [95% CI 0·64–1·31]; p=0·80 for 150 mg S44819 compared with placebo and OR 1·17 [95% CI 0·81–1·67]; p=0·80 for 300 mg S44819 compared with placebo). Likewise, dichotomised mRS scores at day 90 (mRS 0–2 vs 3–6 or mRS 0–1 vs 2–6) did not differ between groups. Secondary endpoints did not reveal any significant group differences. The median NIHSS score at day 90 did not differ between groups (4 [IQR 2–8] in 150 mg S44819 group, 4 [2–7] in 300 mg S44819 group, and 4 [2–6] in placebo group), nor did the number of patients at day 90 with an NIHSS score of up to 5 (95 [61%] of 156 in 150 mg S44819 group, 106 [66%] of 161 in 300 mg S44819 group, and 104 [66%] of 157 in placebo group) versus more than 5 (61 [39%] in 150 mg S44819 group, 55 [34%] in 300 mg S44819 group, and 53 [34%] in placebo group). Likewise, the median MoCA score (22·0 [IQR 17·0–26·0] in 150 mg S44819 group, 23·0 [19·0–26·5] in 300 mg S44819 group, and 22·0 [17·0–26·0] in placebo group), time needed to complete parts A (50 s [IQR 42–68] in 150 mg S44819 group, 49 s [36–63] in 300 mg S44819 group, and 50 s [38–68] in placebo group) and B (107 s [81–144] in 150 mg S44819 group, 121 s [76–159] in 300 mg S44819 group, and 130 s [86–175] in placebo group) of the Trail Making Test, and the Barthel index (90 [IQR 60–100] in 150 mg S44819 group, 90 [70–100] in 300 mg S44819 group, and 90 [70–100] in placebo group) were similar in all groups. Number and type of adverse events were similar between the three groups. There were no drug-related adverse events and no drug-related deaths. Interpretation: There was no evidence that S44819 improved clinical outcome in patients after ischaemic stroke, and thus S44819 cannot be recommended for stroke therapy. The concept of tonic inhibition after stroke should be re-evaluated in humans. Funding: Servier
Italian guidelines for primary headaches: 2012 revised version
The first edition of the Italian diagnostic and therapeutic guidelines for primary headaches in adults was published in J Headache Pain 2(Suppl. 1):105–190 (2001). Ten years later, the guideline committee of the Italian Society for the Study of Headaches (SISC) decided it was time to update therapeutic guidelines. A literature search was carried out on Medline database, and all articles on primary headache treatments in English, German, French and Italian published from February 2001 to December 2011 were taken into account. Only randomized controlled trials (RCT) and meta-analyses were analysed for each drug. If RCT were lacking, open studies and case series were also examined. According to the previous edition, four levels of recommendation were defined on the basis of levels of evidence, scientific strength of evidence and clinical effectiveness. Recommendations for symptomatic and prophylactic treatment of migraine and cluster headache were therefore revised with respect to previous 2001 guidelines and a section was dedicated to non-pharmacological treatment. This article reports a summary of the revised version published in extenso in an Italian version
Particle Image Velocimetry in Helicopter Aerodynamics: Developments, Challenges and Trends
New developments in measurement technology keep driving our experimental capabilities with regard to helicopter
aerodynamics. The inherently unsteady nature of the helicopter flow field and the technical complexity of helicopter itself present a vast number of specific challenges to experimentalists. To illustrate the impact of the technological advancements on the way we study helicopter aerodynamics over the past two decades, we present some recent Particle Image Velocimetry (PIV) applications on blade tip vortices and dynamic stall, assessing the particular demands of studying rotary wing flows. We focus on time-resolved, tomographic and large-scale PIV applications. Furthermore, the combination of PIV with complementary measurement techniques like Background Oriented Schlieren method (BOS) is discussed and its potential contribution to a more detailed understanding of the underlying aerodynamics effects is outlined. Based on some foreseeable trends, finally, a glimpse into the future of PIV in helicopter aerodynamics is ventured
Particle Image Velocimetry in Helicopter Aerodynamics: Developments, Challenges and Trends
Characterisation of blade tip vortices by simultaneous time-resolved velocity and density field measurements
The flow field around a helicopter is dominated by strong coherent vortices originating from the blade tip as a result of the pressure difference between suction and pressure side and a high radial velocity at the tip (Leishman, 2001; Green and Acosta, 1991). These vortices have a strong impact on the rotorcraft acoustics and performance due to its interactions with the rotor blades and the helicopter fuselage (Conlisk, 2001). Detailed knowledge of the vortex development, in particular of the formation process, and the scaling of characteristic parameters, e.g. vortex size and strength, are necessary for the design and the optimisation of vortex control measures. Due to the complexity and the inherent unsteady character of the vortex dynamics, this can only be achieved by time-resolved measurements of the velocity and density field simultaneously
Characterisation of blade tip vortices by simultaneous time-resolved velocity and density field measurements
The flow field around a helicopter is dominated by strong coherent vortices originating from
the blade tip as a result of the pressure difference between suction and pressure side and a high
radial velocity at the tip (Leishman, 2001; Green and Acosta, 1991). These vortices have a strong
impact on the rotorcraft acoustics and performance due to its interactions with the rotor blades
and the helicopter fuselage (Conlisk, 2001). Detailed knowledge of the vortex development, in
particular of the formation process, and the scaling of characteristic parameters, e.g. vortex size
and strength, are necessary for the design and the optimisation of vortex control measures. Due
to the complexity and the inherent unsteady character of the vortex dynamics, this can only be
achieved by time-resolved measurements of the velocity and density field simultaneously
Dynamic stall development
Dynamic stall on an oscillating airfoil was investigated by a combination of surface pressure measurements and time-resolved particle image velocimetry. Following up on previous work on the onset of dynamic stall (Mulleners and Raffel in Exp Fluids 52(3):779-793, 2012), we combined time-resolved imaging with an extensive coherent structure analysis to study various aspects of stall development. The formation of the primary dynamic stall vortex was identified as the growth of a recirculation region and the ensuing instability of the associated shear layer. The stall development can be subdivided into two stages of primary and secondary instability with the latter being the effective vortex formation stage. The characteristic time scales associated with the primary instability stage revealed an overall decrease in dynamic stall delay with increasing effective unsteadiness of the pitching airfoil. The vortex formation stage was found to be largely unaffected by variations of the airfoil’s dynamics
- …